Risk factors for SARS-CoV-2 infection and epidemiological profile of Brazilian anesthesiologists during the COVID-19 pandemic: cross-sectional study.

INTRODUCTION: The devasting effects of COVID-19 have caused economic and health impacts worldwide. Anesthesiologists were one of the key professionals fighting the pandemic and have been highly exposed at their multiple sites of clinical practice. Thus, the importance of determining the nature of the infection in this population that provides care to SARS-CoV-2 patients. METHOD: We conducted a cross-sectional study administering an online questionnaire to examine the demographic and epidemiological profile of these professionals in Brazil, and to describe the risk factors for viral infection during the pandemic. RESULTS: A total of 1,127 anesthesiologists answered the questionnaire, 55.2% were men, more than 90% with age below 60 years, with infection and reinfection rates of 14.7% and 0.5%, respectively, and 47.2% reported a significant income reduction. The predictors of COVID-19 contamination were practicing in operating rooms (OR = 0.42; 95% CI 0.23-0.78), direct contact with infected patients (OR = 5.74; 95% CI 3.05-11.57), indirect contact with infected patients (OR = 2.43; 95% CI 1.13-5.33), working in a pre-hospital setting (OR = 2.36; 95% CI 1.04-5.03), and presence of immunosuppression, except for cancer (OR = 4.89; 95% CI 1.16-19.01). CONCLUSION: COVID-19 had enormous consequences on Brazilian anesthesiologists regarding sociodemographic aspects and contamination rates (5.57 times higher than in the general population). These are alarming and unprecedented findings for this professional group, as they reveal the considerable risk of infection and its independent predictor variables.

Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial.

Importance: Early-stage chronic kidney disease (CKD) characterized by microalbuminuria is associated with future cardiovascular events, progression toward end-stage renal disease, and early mortality in patients with type 2 diabetes. Objective: To compare the albuminuria-lowering effects of Roux-en-Y gastric bypass (RYGB) surgery vs best medical treatment in patients with early-stage CKD, type 2 diabetes, and obesity. Design, Setting, and Participants: For this randomized clinical trial, patients with established type 2 diabetes and microalbuminuria were recruited from a single center from April 1, 2013, through March 31, 2016, with a 5-year follow-up, including prespecified intermediate analysis at 24-month follow-up. Intervention: A total of 100 patients with type 2 diabetes, obesity (body mass indexes of 30 to 35 [calculated as weight in kilograms divided by height in meters squared]), and stage G1 to G3 and A2 to A3 CKD (urinary albumin-creatinine ratio [uACR] >30 mg/g and estimated glomerular filtration rate >30 mL/min) were randomized 1:1 to receive best medical treatment (n = 49) or RYGB (n = 51). Main Outcomes and Measures: The primary outcome was remission of albuminuria (uACR <30 mg/g). Secondary outcomes were CKD remission rate, absolute change in uACR, metabolic control, other microvascular complications, quality of life, and safety. Results: A total of 100 patients (mean [SD] age, 51.4 [7.6] years; 55 [55%] male) were randomized: 51 to RYGB and 49 to best medical care. Remission of albuminuria occurred in 55% of patients (95% CI, 39%-70%) after best medical treatment and 82% of patients (95% CI, 72%-93%) after RYGB (P = .006), resulting in CKD remission rates of 48% (95% CI, 32%-64%) after best medical treatment and 82% (95% CI, 72%-92%) after RYGB (P = .002). The geometric mean uACRs were 55% lower after RYGB (10.7 mg/g of creatinine) than after best medical treatment (23.6 mg/g of creatinine) (P < .001). No difference in the rate of serious adverse events was observed. Conclusions and Relevance: After 24 months, RYGB was more effective than best medical treatment for achieving remission of albuminuria and stage G1 to G3 and A2 to A3 CKD in patients with type 2 diabetes and obesity. Trial Registration: ClinicalTrials.gov Identifier: NCT01821508.